Sugammadex Mylan Ευρωπαϊκή Ένωση - Ρουμανικά - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - blocaj blocant - toate celelalte produse terapeutice - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Teriflunomide Mylan Ευρωπαϊκή Ένωση - Ρουμανικά - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomidă - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

PERINDOPRIL ARGININA MYLAN 10 mg Ρουμανία - Ρουμανικά - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

perindopril arginina mylan 10 mg

mcdermott laboratories ltd trading as gerard lab. - irlanda - perindoprilum - compr. film. - 10mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei

PERINDOPRIL ARGININA MYLAN 2,5 mg Ρουμανία - Ρουμανικά - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

perindopril arginina mylan 2,5 mg

mcdermott laboratories ltd trading as gerard lab. - irlanda - perindoprilum - compr. film. - 2,5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei

PERINDOPRIL ARGININA MYLAN 5 mg Ρουμανία - Ρουμανικά - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

perindopril arginina mylan 5 mg

mcdermott laboratories ltd trading as gerard lab. - irlanda - perindoprilum - compr. film. - 5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei

ABACAVIR/LAMIVUDINA MYLAN 600 mg/300 mg Ρουμανία - Ρουμανικά - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abacavir/lamivudina mylan 600 mg/300 mg

mylan s.a.s. (saint priest) - franta - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii

ABACAVIR/LAMIVUDINA MYLAN 600 mg/300 mg Ρουμανία - Ρουμανικά - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abacavir/lamivudina mylan 600 mg/300 mg

mylan s.a.s. (saint priest) - franta - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii

LEVOFLOXACINA MYLAN 500 mg/100 ml Ρουμανία - Ρουμανικά - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

levofloxacina mylan 500 mg/100 ml

mylan s.a.s. - franta - levofloxacinum - sol. perf. - 500mg/100ml - chinolone antibacteriene fluorochinolone

Docetaxel Mylan Ευρωπαϊκή Ένωση - Ρουμανικά - EMA (European Medicines Agency)

docetaxel mylan

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - agenți antineoplazici - tratamentul cancerului mamar, forme speciale de cancer pulmonar (cancer pulmonar celule mici), cancer de prostata, gastric cancer sau cancer de cap şi gât.

Fingolimod Mylan Ευρωπαϊκή Ένωση - Ρουμανικά - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod clorhidrat de - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 și 5. 1)orpatients cu evoluție rapidă severă scleroză multiplă recurentă remisivă definită prin 2 sau mai multe recidive care produc invaliditate într-un an și cu 1 sau mai multe leziuni evidențiate cu gadoliniu la irm craniană sau o creștere semnificativă a încărcării leziunilor t2 comparativ cu o irm anterioară recentă.